You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Atopic Dermatitis Updates

  • Authors: Katrina Abuabara, MD, MA, MSCE; April W. Armstrong, MD, MPH; Lawrence F. Eichenfield, MD; Brian S. Kim, MD, MTR; Peter A. Lio, MD; Robert Sidbury, MD, MPH
  • CME / ABIM MOC / CE Released: 5/17/2022
  • Valid for credit through: 5/17/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.50 ABIM MOC points

    Nurses - 1.50 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for dermatologists, allergists and clinical immunologists, primary care physicians (PCPs), pediatricians, nurses, nurse practitioners (NPs), and physician assistants (PAs) involved in the care of patients with atopic dermatitis (AD).

The goal of this activity is that learners will be better able to manage their patients with AD.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data on new and emerging topical AD medications
    • Data regarding targeted systemic agents for AD  
    • Effects of different AD treatments on clinical symptoms
    • Evidence on safety and efficacy for targeted oral AD treatments
  • Have greater competence related to
    • Selecting AD treatments that consider patient-related factors, such as age, severity, Fitzpatrick skin type, and comorbid conditions
  • Demonstrate greater confidence in their ability to 
    • Manage patients with AD


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Katrina Abuabara, MD, MA, MSCE

    Associate Professor
    Department of Dermatology
    University of California San Francisco
    San Francisco, California

    Disclosures

    Disclosure: Katrina Abuabara, MD, MA, MSCE, has the following relevant financial relationships: 
    Consultant or advisor for: Target RWE
    Research funding from: Cosmetique; Pfizer

  • April W. Armstrong, MD, MPH

    Professor of Dermatology
    Associate Dean of Clinical Research
    Keck School of Medicine
    University of Southern California
    Los Angeles, California

    Disclosures

    Disclosure: April W. Armstrong, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Almirall; Arcutis; ASLAN; Beiersdorf; Boehringer Ingelheim; Bristol Myers Squibb Company; Dermavant; Dermira; EPI; Incyte; Janssen; Leo; Lilly; Modmed; Nimbus; Novartis; Ortho; Pfizer; Regeneron; Sanofi; Sun; UCB
    Speaker or member of speakers bureau for: AbbVie; ASLAN; Boehringer Ingelheim; Bristol Myers Squibb Company; Dermatologics; Dermavant; Dermira; EPI; Incyte; Janssen; Leo; Lilly; Novartis; Ortho; Parexel; Pfizer; Sanofi; Sun; UCB
    Research funding from: AbbVie; Bristol Myers Squibb Company; Dermavant; Dermira; Galderma; Incyte; Janssen; Kyowa Kirin; Leo; Lilly; Novartis; Pfizer; Regeneron; UCB

  • Lawrence F. Eichenfield, MD

    Chief, Pediatric and Adolescent Dermatology
    Professor, Dermatology and Pediatrics
    Vice Chair, Department of Dermatology
    University of California
    San Diego School of Medicine
    Rady Children's Hospital
    San Diego, California

    Disclosures

    Disclosure: Lawrence F. Eichenfield, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Almirall; Arcutis; Arena; ASLAN; Castle Creek; Dermavant; Forté; Galderma; Glenmark; Ichnos; Incyte; Krystal Bio; Leo; Lilly; Novartis; Ortho; Otsuka; Pfizer; Regeneron; Sanofi; Verrica
    Speaker or member of speakers bureau for: Incyte; Krystal Bio; Leo; Novartis; Regeneron; Sanofi
    Research funding from: AbbVie; Bausch; Galderma; Pfizer
    Stock options from: Forté; Verrica
    Monetary compensation for an executive role from: Forté; Verrica

  • Brian S. Kim, MD, MTR

    Sol and Clara Kest Professor
    Vice Chair of Research
    Kimberly and Eric J. Waldman
    Department of Dermatology
    Icahn School of Medicine at Mount Sinai
    New York, New York

    Disclosures

    Disclosure: Brian S. Kim, MD, MTR, has no relevant financial relationships.

  • Peter A. Lio, MD

    Clinical Assistant Professor of Dermatology and Pediatrics
    Northwestern University Feinberg School of Medicine
    Founding Director, Chicago Integrative Eczema Center
    Founding Partner, Medical Dermatology Associates of Chicago
    Chicago, Illinois

    Disclosures

    Disclosure: Peter A. Lio, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Almirall; Altus Labs; Amyris; AOBiome; Arbonne; ASLAN; Bodewell; Boston Skin Science; Burt's Bees; Castle Biosciences; Concerto; Dermavant; Exeltis; Galderma; IntraDerm; Janssen; Johnson & Johnson; Kaleido; Kimberly-Clark; KP Away; Leo; Level Ex; Lilly; Lipidor; L'Oreal; Menlo; Micreos; MyOR Diagnostics; Pierre Fabre; Pfizer; Realm; Regeneron; Sanofi; Theraplex; Unilever; Verrica; YobeeCare
    Speaker or member of speakers bureau for: AbbVie; Galderma; Incyte; Leo; L'Oreal; Pfizer; Regeneron; Sanofi
    Research funding from: AbbVie; AOBiome; Regeneron; Sanofi
    Contracted researcher for: AbbVie; AOBiome; Regeneron; Sanofi
    Royalties from: Theraplex
    Patent beneficiary of: Theraplex
    Stock options from: Altus; Boston Skin Science; Concerto; KP Away; Micreos; YobeeCare

  • Robert Sidbury, MD, MPH

    Professor, Department of Pediatrics
    Chief, Division of Dermatology, Seattle Children's Hospital
    University of Washington School of Medicine
    Seattle, Washington

    Disclosures

    Disclosure: Robert Sidbury, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: Leo
    Speaker or member of speakers bureau for: Beiersdorf
    Research funding from: Galderma; Pfizer; Regeneron; UCB

Editors

  • Meghan Coulehan, MPH

    Senior Director, Content Development, Medscape, LLC

    Disclosures

    Disclosure: Meghan Coulehan, MPH, has no relevant financial relationships.

  • Roderick Smith, MS

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Roderick Smith, MS, has no relevant financial relationships.

  • Faisal Islam, MD, MBA

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Faisal Islam, MD, MBA, has no relevant financial relationships.

Compliance Reviewer

  • Esther Nyarko, PharmD

    Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Atopic Dermatitis Updates

Authors: Katrina Abuabara, MD, MA, MSCE; April W. Armstrong, MD, MPH; Lawrence F. Eichenfield, MD; Brian S. Kim, MD, MTR; Peter A. Lio, MD; Robert Sidbury, MD, MPHFaculty and Disclosures

CME / ABIM MOC / CE Released: 5/17/2022

Valid for credit through: 5/17/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Atopic Dermatitis: Course and Comorbidities Across the Lifespan

Hear about the natural course of AD and associated comorbidities.
Katrina Abuabara, MD, MA, MSCE

The Topical AD Toolbox

Dr Eichenfield reviews the latest developments on topical AD treatments.
Lawrence F. Eichenfield, MD

New Data on Biologics for Atopic Dermatitis

Dr Armstrong presents new data about biologics in development for AD.
April W. Armstrong, MD, MPH

The Evolving Landscape of Oral Systemic AD Therapies

JAK inhibitors and oral systemic agents are reviewed in this talk.
Peter A. Lio, MD

The Itch Factor

Dr Kim explains the science of itch in AD and which agents best address it.
Brian S. Kim, MD, MTR

Atopic Dermatitis Guidelines in Context

Dr Sidbury reviews AD guidelines in the context of new and emerging treatments.
Robert Sidbury, MD, MPH
 

Educational Impact Challenge

The goal of this activity is that learners will be better able to manage their patients with AD.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print